Please assess the completion status of the following clinical trial:

Trial Title: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histologically or cytologically documented breast cancer (Cohort A) with known or suspected parenchymal brain metastases.~* Recurrent glioblastoma (Cohort B) with documented progression by RANO criteria following standard combined modality treatment with radiation and temozolomide.~* Plans to undergo craniotomy as part of standard of care. Patients emergently needing surgical debulking due to symptoms of their disease are not eligible.~* Recovered from toxicities of prior therapy to grade 0 or 1~* ECOG performance status ≤ 2.~* Life expectancy of at least 3 months.~* Acceptable liver function:~* Bilirubin ≤ 1.5 times upper limit of normal~* AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);~* Adequate renal function: calculated creatinine clearance ≥30mL/minute according to the Cockcroft and Gault formula~* Acceptable hematologic status (without hematologic support)~* ANC ≥1500 cells/uL~* Platelet count ≥100,000/uL~* Hemoglobin ≥9.0 g/dL~* All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.~Exclusion Criteria:~* The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.~* The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.~* The subject is unable to undergo MRI scan (eg, has pacemaker).~* The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).~* Patients whose only lesion undergoing resection has received stereotactic radiation within the past 3 months~* The subject has received any of the following prior anticancer therapy:~  * Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug~ * Prior treatment with Sacituzumab Govitecan~* Patients receiving UGT1A1 (Uridine diphosphate glucuronosyl transferase 1A1) inhibitors or inducers.~* History of significant cardiovascular disease, defined as:~  * Congestive heart failure greater than New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.~ * Unstable angina or myocardial infarction within 6 months before enrollment.~ * Serious cardiac arrhythmia.~* Clinically significant ECG abnormality, including:~  * Marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval \>500 ms) demonstrated on ECG at Screening.~ * History of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome).~* Any medical or other condition which, in the opinion of the Investigator, causes the subject to be medically unfit to receive Sacituzumab Govitecan, or unsuitable for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Brain Metastasis and Glioblastoma (Type: EXPERIMENTAL): Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).